Relationship of anabolic and catabolic biomarkers with muscle strength and physical performance in older adults: A population-based cross-sectional study

BMC Musculoskeletal Disorders

Volumn 16, Issue 1, 2015, Pages

  Meng, Yongxia ^a   Wu, Hongmei ^b   Yang, Yi ^c   Du, Huanmin ^b   Xia, Yang ^b   Guo, Xiaoyan ^b   Liu, Xing ^b   Li, Chunlei ^b   Niu, Kaijun ^b  

^a Chinese PLA 254 Hospital   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c Tianjin Centers for Disease Control and Prevention   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; PRASTERONE SULFATE; SOMATOMEDIN C; AUTACOID; BIOLOGICAL MARKER;

AGED; ANALYSIS OF COVARIANCE; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DYNAMOMETRY; FEMALE; GRIP STRENGTH; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE FUNCTION; MUSCLE MASS; MUSCLE STRENGTH; PHYSICAL ACTIVITY; PHYSICAL PERFORMANCE; POPULATION RESEARCH; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; WALKING SPEED; BLOOD; FITNESS; HEALTH SURVEY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; SARCOPENIA;

AGED; BIOMARKERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; METABOLISM; MIDDLE AGED; MUSCLE STRENGTH; PHYSICAL FITNESS; POPULATION SURVEILLANCE; SARCOPENIA;

EID: 84939238497     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/s12891-015-0654-7     Document Type: Article

References (40)

1. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39:412-23.
2. Xue QL, Walston JD, Fried LP, Beamer BA. Prediction of risk of falling, physical disability, and frailty by rate of decline in grip strength: the women's health and aging study. Arch Intern Med. 2011;171:1119-21.
3. Dufour AB, Hannan MT, Murabito JM, Kiel DP, McLean RR. Sarcopenia definitions considering body size and fat mass are associated with mobility limitations: the Framingham Study. J Gerontol A Biol Sci Med Sci. 2013;68:168-74.
4. Landi F, Cruz-Jentoft AJ, Liperoti R, Russo A, Giovannini S, Tosato M, et al. Sarcopenia and mortality risk in frail older persons aged 80 years and older: results from ilSIRENTE study. Age Ageing. 2013;42:203-9.
5. Hamer M, Molloy GJ. Association of C-reactive protein and muscle strength in the English Longitudinal Study of Ageing. Age. 2009;31:171-7.
6. Yu Z, Ye X, Wang J, Qi Q, Franco OH, Rennie KL, et al. Associations of physical activity with inflammatory factors, adipocytokines, and metabolic syndrome in middle-aged and older chinese people. Circulation. 2009;119:2969-77.
7. Brinkley TE, Leng X, Miller ME, Kitzman DW, Pahor M, Berry MJ, et al. Chronic inflammation is associated with low physical function in older adults across multiple comorbidities. J Gerontol A Biol Sci Med Sci. 2009;64:455-61.
8. Cesari M, Penninx BW, Pahor M, Lauretani F, Corsi AM, Rhys Williams G, et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2004;59:242-8.
9. Niu K, Hozawa A, Guo H, Ohmori-Matsuda K, Cui Y, Ebihara S, et al. C-reactive protein (CRP) is a predictor of high medical-care expenditures in a community-based elderly population aged 70 years and over: the Tsurugaya project. Arch Gerontol Geriatr. 2012;54:e392-7.
10. Brioche T, Kireev RA, Cuesta S, Gratas-Delamarche A, Tresguerres JA, Gomez-Cabrera MC, et al. Growth hormone replacement therapy prevents Sarcopenia by a dual mechanism: improvement of protein balance and of antioxidant defenses. J Gerontol A Biol Sci Med Sci. 2013;69(10):1186-98.
11. Bonnefoy M, Patricot MC, Lacour JR, Rahmani A, Berthouze S, Kostka T. Relation between physical activity, muscle function and IGF-1, testosterone and DHEAS concentrations in the elderly. Rev Med Interne. 2002;23:819-27.
12. Taekema DG, Ling CH, Blauw GJ, Meskers CG, Westendorp RG, de Craen AJ, et al. Circulating levels of IGF1 are associated with muscle strength in middle-aged- and oldest-old women. Eur J Endocrinol. 2011;164:189-96.
13. Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol. 2006;17:1807-19.
14. Hoffman EP, Nader GA. Balancing muscle hypertrophy and atrophy. Nat Med. 2004;10:584-5.
15. Morley JE. Sarcopenia in the elderly. Fam Pract. 2012;29 Suppl 1:i44-i8.
16. Pollanen E, Ronkainen PH, Horttanainen M, Takala T, Puolakka J, Suominen H, et al. Effects of combined hormone replacement therapy or its effective agents on the IGF-1 pathway in skeletal muscle. Growth Horm IGF Res. 2010;20:372-9.
17. Sakuma K, Yamaguchi A. Sarcopenia and age-related endocrine function. Int J Endocrinol. 2012;2012:127362.
18. McIntire KL, Hoffman AR. The endocrine system and sarcopenia: potential therapeutic benefits. Curr Aging Sci. 2011;4:298-305.
19. Haren MT, Malmstrom TK, Miller DK, Patrick P, Perry 3rd HM, Herning MM, et al. Higher C-reactive protein and soluble tumor necrosis factor receptor levels are associated with poor physical function and disability: a cross-sectional analysis of a cohort of late middle-aged African Americans. J Gerontol A Biol Sci Med Sci. 2010;65:274-81.
20. Kilgour RD, Vigano A, Trutschnigg B, Lucar E, Borod M, Morais JA. Handgrip strength predicts survival and is associated with markers of clinical and functional outcomes in advanced cancer patients. Support Care Cancer. 2013;21:3261-70.
21. Ling CH, Taekema D, de Craen AJ, Gussekloo J, Westendorp RG, Maier AB. Handgrip strength and mortality in the oldest old population: the Leiden 85-plus study. CMAJ. 2010;182:429-35.
22. Wind AE, Takken T, Helders PJ, Engelbert RH. Is grip strength a predictor for total muscle strength in healthy children, adolescents, and young adults? Eur J Pediatr. 2010;169:281-7.
23. Studenski S, Perera S, Patel K, Rosano C, Faulkner K, Inzitari M, et al. Gait speed and survival in older adults. JAMA. 2011;305:50-8.
24. Abellan van Kan G, Rolland Y, Andrieu S, Bauer J, Beauchet O, Bonnefoy M, et al. Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people an International Academy on Nutrition and Aging (IANA) Task Force. J Nutr Health Aging. 2009;13:881-9.
25. Hall WJ. Update in geriatrics. Ann Intern Med. 2006;145:538-43.
26. Bijlsma AY, Meskers MC, Molendijk M, Westendorp RG, Sipila S, Stenroth L, et al. Diagnostic measures for sarcopenia and bone mineral density. Osteoporos Int. 2013;24:2681-91.
27. Panel on Prevention of Falls in Older Persons AGS, British Geriatrics S. Summary of the updated American geriatrics society/British geriatrics society clinical practice guideline for prevention of falls in older persons. J Am Geriatr Soc. 2011;59:148-57.
28. Barry E, Galvin R, Keogh C, Horgan F, Fahey T. Is the Timed Up and Go test a useful predictor of risk of falls in community dwelling older adults: a systematic review and meta- analysis. BMC Geriatr. 2014;14:14.
29. Castell MV, Sanchez M, Julian R, Queipo R, Martin S, Otero A. Frailty prevalence and slow walking speed in persons age 65 and older: implications for primary care. BMC Fam Pract. 2013;14:86.
30. Peel NM, Kuys SS, Klein K. Gait speed as a measure in geriatric assessment in clinical settings: a systematic review. J Gerontol A Biol Sci Med Sci. 2013;68:39-46.
31. Guidelines for data processing and analysis of the International Physical Activity Questionnaire (IPAQ). 2005. http://www.institutferran.org/documentos/scoring-short-ipaq-april04.pdf. Accessed 1 October 2014.
32. Wannamethee SG, Lowe GD, Whincup PH, Rumley A, Walker M, Lennon L. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation. 2002;105:1785-90.
33. Schaap LA, Pluijm SM, Deeg DJ, Visser M. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med. 2006;119(526):e9-17.
34. Bodell PW, Kodesh E, Haddad F, Zaldivar FP, Cooper DM, Adams GR. Skeletal muscle growth in young rats is inhibited by chronic exposure to IL-6 but preserved by concurrent voluntary endurance exercise. J Appl Physiol. 2009;106(1985):443-53.
35. Bonaldo P, Sandri M. Cellular and molecular mechanisms of muscle atrophy. Dis Model Mech. 2013;6:25-39.
36. Peterson JM, Bakkar N, Guttridge DC. NF-kappaB signaling in skeletal muscle health and disease. Curr Top Dev Biol. 2011;96:85-119.
37. Lippi G, Sanchis-Gomar F, Montagnana M. Biological markers in older people at risk of mobility limitations. Curr Pharm Des. 2014;20:3222-44.
38. Giovannini S, Marzetti E, Borst SE, Leeuwenburgh C. Modulation of GH/IGF-1 axis: potential strategies to counteract sarcopenia in older adults. Mech Ageing Dev. 2008;129:593-601.
39. Schertzer JD, Lynch GS. Comparative evaluation of IGF-I gene transfer and IGF-I protein administration for enhancing skeletal muscle regeneration after injury. Gene Ther. 2006;13:1657-64.
40. Maggio M, Lauretani F, Ceda GP. Sex hormones and sarcopenia in older persons. Curr Opin Clin Nutr Metab Care. 2013;16:3-13.